European Commission contributes close to EUR 2 million to the Joint Programming Initiative on Alzheimer’s disease and neurodegenerative diseases
Thursday 15 April 2010
The European Commission will be supporting the work of the Joint Programming Initiative on Alzheimer’s disease and neurodegenerative diseases (JPND) with an EU contribution of close to EUR 2 million.
The European Commission welcomes the first meeting of the Scientific Advisory Board of this very first EU Joint Programming Initiative (15 April, Stockholm).
The Scientific Advisory Board gathers 15 of the top neurodegenerative disease scientists from Europe and elsewhere in the world. Its role is to advise on the development and implementation on the JPND. Professor Philippe Amouyel, from France, chairs this new initiative Management Board.
The ultimate goal of the JPND is to accelerate progress in understanding the causes of these debilitating conditions, leading to early diagnosis, the development of new treatments and prevention and the provision of more effective medical and social care to improve the quality of life for patients and care givers.
To achieve this goal, 24 European countries, sharing a common vision, have decided to work together in an unprecedented collaborative initiative in research which is seeking to align their scientific competencies, medical strengths and social approaches to tackle the challenge.
The JPND will start by:
- Developing a strategic research agenda for neurodegenerative diseases encompassing basic, clinical and social research, with the latter also including models of healthcare delivery.
- Implementing that agenda by proposing innovative ways of pooling expertise and resources to address the fragmentation and duplication of current research efforts.
Weblinks
http://www.neurodegenerationresearch.eu/news/
http://ec.europa.eu/health/major_chronic_diseases/diseases/alzheimer/index_en.htm
MEMO/09/346